Inhibition of JAK kinase activity enhances fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4262-4271

  Oshiro, M M ^a   Landowski, T H ^a   Catlett Falcone, R ^a   Hazlehurst, L A ^a   Huang, M ^a   Jove, R ^a   Dalton, W S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CYCLIN D1; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; JANUS KINASE; JANUS KINASE INHIBITOR; MELPHALAN; MITOXANTRONE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MULTIPLE MYELOMA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0035678875     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Multiple myeloma: Increasing evidence for a multistep transformation process
2. Myeloma biology and therapy: Present status and future developments
3. Mechanisms of drug resistance in hematologic malignancies
4. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumorigenesis and resistance to chemotherapy
5. Double identity for proteins of the Bcl-2 family
6. Molecular thanatopsis: A discourse on the Bcl2 family and cell death
7. Bcl-2 and Bcl-XL can differentially block chemotherapy induced cell death
8. Bcl-XL protects primary B cells against Fas-mediated apoptosis
9. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
10. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
11. STATs in oncogenesis
12. STATs and gene regulation
13. Signaling through the hematopoietic cytokine receptors
14. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ
15. Regulation of STAT-dependent pathways by growth factors and cytokines
16. Activated Stat related transcription factors in acute leukemia
17. The JAK-STAT pathway: Signal transduction involved in proliferation, differentiation and transformation
18. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome
19. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins
20. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
21. STAT signaling in head and neck cancer
22. Drug resistance in multiple myeloma: Approaches to circumvention
23. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated taxol resistance
24. The comet moment as a measure of DNA damage in the comet assay
25. Reduction in drug-induced DNA double strand-breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 leukemia cells
26. Apoptosis by death factor
27. Role for Bcl-xL as an inhibitor of cytosolic cytochrome c accumulation in DNA damaged-induced apoptosis
28. Cytochrome c. Can't live with it - Can't live without it
29. Expression of Bcl-xL can confer a multidrug resistance phenotype
30. Two CD95 (APO-1/Fas) signaling pathways
31. Bcl-2 blocks glucocorticoid but not fas or activation induced apoptosis in a T cell hybridoma
32. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
33. Interleukin-6-type cytokine signalling through the gp130/ Jak/STAT pathway
34. 1-phase progression
35. Stat3 as an oncogene
36. Induction of p21waf/cip1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling
37. Cell death induced by topoisomerase-targeted drugs: More questions than answers
38. Quantitative and cytokinetic studies in experimental tumor models
39. Apoptosis and the dilemma of cancer chemotherapy
40. IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade
41. STAT proteins as novel targets for cancer therapy
42. STAT proteins: Novel molecular targets for cancer drug discovery
43. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo